Nkarta (NKTX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting will be held virtually on June 5, 2025, to elect three Class II directors and ratify the appointment of Ernst & Young LLP as the independent auditor for 2025.
Stockholders of record as of April 10, 2025, are eligible to vote on these matters.
Proxy materials and the 2024 Annual Report are available online, and voting can be done via internet, phone, mail, or during the meeting.
Voting matters and shareholder proposals
Proposals include electing three Class II directors (Michael Dybbs, Simeon George, Leone Patterson) to serve until 2028 and ratifying Ernst & Young LLP as auditor for 2025.
The board recommends voting for all director nominees and for the auditor ratification.
Shareholders may submit proposals for the 2026 annual meeting by December 22, 2025, for inclusion in proxy materials.
Board of directors and corporate governance
The board consists of eight directors divided into three classes with staggered three-year terms.
88% of directors are independent, and the average board tenure is 5.5 years.
The roles of CEO and Chairman are separated; Dr. Behbahani serves as independent Chairman.
Four standing committees: Audit, Compensation, Nominating and Governance, and Science and Technology.
Directors are encouraged to attend annual meetings, and succession planning is periodically reviewed.
Latest events from Nkarta
- Focused on CD19 NK cell therapy for autoimmune disease, advancing toward pivotal trials and outpatient care.NKTX
Leerink Global Healthcare Conference 202610 Mar 2026 - Allogeneic NK cell therapy advances with strong safety, pivotal data expected this year.NKTX
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Allogeneic CAR NK therapy advances in autoimmune diseases, with key data expected in 2025.NKTX
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - Leading allogeneic NK cell trials in autoimmune disease, prioritizing safety and drug-free remission.NKTX
Stifel 2024 Healthcare Conference13 Jan 2026 - Robust, safe, off-the-shelf NK cell therapy targets I&I with key data expected in 2025.NKTX
7th Annual Evercore ISI HealthCONx Healthcare Conference11 Jan 2026 - Allogeneic CAR-NK cells show promise for safe, flexible autoimmune therapy with broad potential.NKTX
TD Cowen 45th Annual Healthcare Conference26 Dec 2025 - Allogeneic CAR-NK therapies show strong safety and scalability for autoimmune diseases, with key data ahead.NKTX
24th Annual Needham Virtual Healthcare Conference23 Dec 2025 - Robust I&I data expected next year, with accelerated enrollment and strong financial runway.NKTX
Evercore ISI 8th Annual HealthCONx Conference7 Dec 2025 - Director elections and auditor ratification headline the June 2025 annual meeting agenda.NKTX
Proxy Filing2 Dec 2025